(NASDAQ: OCS) Oculis Holding Ag's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.91%.
Oculis Holding Ag's earnings in 2026 is -$121,276,923.On average, 12 Wall Street analysts forecast OCS's earnings for 2026 to be -$112,667,865, with the lowest OCS earnings forecast at -$119,777,853, and the highest OCS earnings forecast at -$103,578,745. On average, 12 Wall Street analysts forecast OCS's earnings for 2027 to be -$111,129,229, with the lowest OCS earnings forecast at -$164,770,549, and the highest OCS earnings forecast at -$78,824,076.
In 2028, OCS is forecast to generate -$97,597,918 in earnings, with the lowest earnings forecast at -$155,042,398 and the highest earnings forecast at -$2,605,755.